(Health Korea News / Lee Chung-man) As Eli Lilly and Company of the United States recorded below-expected results in the GLP-1 agonist market, the possibility of Denmark’s Novo Nordisk becoming dominant is growing.
According to Lilly on the 14th (local time), GLP-1 agonists ‘Mounjaro’ (ingredient name: tirzepatide) and ‘Zepbound’ (ingredient name: tirzepatide) will be available in the fourth quarter of 2024. It turned out that the results were somewhat disappointing.
For reference, ‘Maunjaro’ and ‘Zebbound’ are drugs with the same ingredients, only the product names are different. ‘Maunjaro’ was approved as a type 2 diabetes treatment, and ‘Zebbound’ was approved as an obesity treatment.
‘Maunjaro’ and ‘Zebbound’ were tentatively calculated to have generated sales of $3.5 billion (about KRW 5 trillion) and $1.9 billion (about KRW 2.7 trillion), respectively, in the fourth quarter of 2024. The exact figures will be released in February 2025.
This is a record that falls below industry expectations. ‘Maunjaro’ and ‘Jebbound’ were initially predicted to generate profits of $4 billion (about KRW 5.8 trillion) and $2.1 billion (about KRW 3 trillion).
By the third quarter of 2024, the cumulative sales of ‘Maunjaro’ and ‘Zebbound’ are USD 8 billion (approximately KRW 11.6 trillion) and KRW 3 billion (approximately KRW 4.3 trillion), with a combined sales of USD 11 billion. (about KRW 16 trillion).
This is a notable growth compared to the combined sales of $3 billion (approximately KRW 4.3 trillion) in the same period last year, but the rival drug Novo Nordisk’s GLP-1 agonist ‘Ozempic’ (ingredient name: Compared to semaglutide, which achieved sales of $12 billion (approximately KRW 17 trillion) in 9 months in 2024, It’s a shabby result.
In addition to ‘Ozempic’, Novo Nordisk has a portfolio of other GLP-1 agonists, including ‘Wegovy’ (ingredient name: semaglutide) and ‘Rybelsus’ (ingredient name: semaglutide) with the same ingredients. It is predicted that the combined nine-month sales of these product groups in 2024 will reach $20 billion (about KRW 30 trillion). It’s coming out.
Therefore, Novo Nordisk’s leadership position in the GLP-1 agonist market is expected to become more solidified. ‘Ozempic’ is estimated to reap profits of approximately $16 billion (approximately KRW 23.544 trillion) in 2024.
Meanwhile, Lilly said on this day, “We will make every effort to supply at least 60% more GLP-1 product lines in the first half of this year compared to 2024.”
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
